Search

Displaying results 7291 - 7300 of 7654 in total
  1. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine.

  2. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.

  3. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  4. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    Nifurizone has a monoisotopic molecular weight of 307.09 Da.

  5. Drug

    Onametostat

    go.drugbank.com/drugs/DB21480
    Investigational

    Onametostat has a monoisotopic molecular weight of 482.11 Da.

  6. Drug

    Mequitazine

    go.drugbank.com/drugs/DB01071
    Investigational

    It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

  7. Drug

    Nifurethazone

    go.drugbank.com/drugs/DB20112
    Experimental

    Nifurethazone has a monoisotopic molecular weight of 269.11 Da.

  8. Drug

    Gamcemetinib

    go.drugbank.com/drugs/DB21624
    Investigational

    Gamcemetinib has a monoisotopic molecular weight of 469.1 Da.

  9. Drug

    Allylestrenol

    go.drugbank.com/drugs/DB01431
    Investigational

    A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast...

  10. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...